Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 975

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL

Open access
de Zeeuw, Dick, Remuzzi, Giuseppe, Parving, Hans-Henrik, Keane, William F., Zhang, Zhongxin, Shahinfar, Shahnaz, Snapinn, Steve, Cooper, Mark E., Mitch, William E., Brenner, Barry M.·2004·Kidney International
DOI 10.1111/j.1523-1755.2004.00653.x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1523-1755.2004.00653.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 30

  1. Amos, 1997, The rising global burden of diabetes and its complications: Estimates and projections to the year 2010, Diabetes Med, 14, S1
  2. King, 1998, Global burden of diabetes 1995–2025. Prevalence, numerical estimates and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 · DOI · Paper page
  3. Parving, 2001, Diabetic nephropathy: Prevention and treatment, Kidney Int, 60, 2041, 10.1046/j.1523-1755.2001.00020.x · DOI
  4. Remuzzi, 2002, Nephropathy in patients with type 2 diabetes, N Engl J Med, 346, 1145, 10.1056/NEJMcp011773 · DOI · Paper page
  5. Remuzzi, 2002, Chronic renal diseases: renal protective benefits of renin-angiotensin system inhibition, Ann Intern Med, 136, 604, 10.7326/0003-4819-136-8-200204160-00010 · DOI · Paper page
  6. Keane, 2003, The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study, Kidney Int, 63, 1499, 10.1046/j.1523-1755.2003.00885.x · DOI · Paper page
  7. Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 · DOI · Paper page
  8. De Jong, 1999, Renoprotective therapy: Titration against urinary protein excretion, Lancet, 354, 352, 10.1016/S0140-6736(99)90122-8 · DOI
  9. Brenner, 2000, The losartan renal protection study—Rationale, study design and baseline characteristics of RENAAL (Reduction of End Points in NIDDM with the Angiotensin II Antagonist Losartan), JRAAS, 1, 328
  10. Williams, 1988, Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure, Q J Med, 67, 343
  11. Remuzzi, 1990, Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?, Kidney Int, 38, 384, 10.1038/ki.1990.217 · DOI · Paper page
  12. Rossing, 1993, Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients, Diabetes, 42, 715, 10.2337/diab.42.5.715 · DOI
  13. Breyer, 1996, Predictors of the progression of renal insufficiency in patients with insulin dependent diabetes and over diabetic nephropathy, Kidney Int, 50, 1651, 10.1038/ki.1996.481 · DOI · Paper page
  14. Yokoyama, 1997, Predictors of the progression of diabetic nephropathy and the beneficial effect of ACEi in NIDDM patients, Diabetologia, 40, 405, 10.1007/s001250050694 · DOI
  15. Peterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease. MDRD, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003 · DOI · Paper page
  16. Parving, 2001, Evolving strategies for renoprotection: Diabetic nephropathy, Curr Opin Nephrol Hypertens, 10, 515, 10.1097/00041552-200107000-00006 · DOI
  17. Bianchi, 2003, A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease, Am J Kidney Dis, 41, 565, 10.1053/ajkd.2003.50140 · DOI · Paper page
  18. El Nahas, 1984, Selective effect of low protein diets in chronic renal diseases, Br Med J (Clin Res), 289, 1337, 10.1136/bmj.289.6455.1337 · DOI
  19. Vriesendorp, 1986, Effects of nonsteroidal anti-inflammatory drugs on proteinuria, Am J Med, 81, 84, 10.1016/0002-9343(86)90910-1 · DOI
  20. Kasiske, 1993, Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis, Ann Intern Med, 118, 129, 10.7326/0003-4819-118-2-199301150-00009 · DOI · Paper page
  21. Gansevoort, 1995, Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials, Nephrol Dial Transplant, 10, 1963
  22. Gansevoort, 1994, Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?, Kidney Int, 45, 861, 10.1038/ki.1994.113 · DOI · Paper page
  23. Perico, 1998, The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin, J Am Soc Nephrol, 9, 2308, 10.1681/ASN.V9122308 · DOI
  24. Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 · DOI · Paper page
  25. The GISEN Group, 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
  26. Rossing, 1994, Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment, Diabetologia, 37, 511, 10.1007/s001250050140 · DOI · Paper page
  27. Apperloo, 1994, Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease, Kidney Int, 45, S174
  28. Laverman, 2001, Optimal antiproteinuric dose of losartan in non-diabetic patients with nephrotic range proteinuria, Am J Kidney Dis, 38, 1381, 10.1053/ajkd.2001.29262 · doi:10.1053/ajkd.2001.29262
  29. Andersen, 2002, Optimal dose of losartan for renoprotection in diabetic nephropathy, Nephrol Dial Transplant, 17, 1413, 10.1093/ndt/17.8.1413 · DOI
  30. Weinberg, 2001, The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein secretion, JRAAS, 2, S196

Cited by

See all 975

Metadata

Authors
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M.
Venue
Kidney International
Publisher
Elsevier BV
Published
2004-06
Volume
65
Issue
6
Pages
2309-2320
ISSN
0085-2538 (ISSN-L)
DOI
10.1111/j.1523-1755.2004.00653.x
OpenAlex
W2017268330
Cited by
975
References
4
FWCI
40.63
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. https://app.cochat.ai/papers/10.1111/j.1523-1755.2004.00653.x
The paper
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004). Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International. https://doi.org/10.1111/j.1523-1755.2004.00653.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.